What is the appropriate management of ventricular tachycardia (VT) and supraventricular tachycardia (SVT)?

Management of Ventricular Tachycardia (VT) and Supraventricular Tachycardia (SVT)

For hemodynamically unstable patients with either VT or SVT, perform immediate synchronized cardioversion; for stable SVT, start with vagal maneuvers followed by adenosine, while stable VT requires careful assessment of underlying structural heart disease and consideration of antiarrhythmic drugs or cardioversion.

Supraventricular Tachycardia (SVT) Management

Acute Management - Hemodynamically Unstable Patients

Immediate synchronized cardioversion is mandatory for any SVT causing hypotension, altered mental status, shock, chest pain, or acute heart failure 1. Do not delay with pharmacologic attempts in unstable patients—cardioversion successfully restores sinus rhythm in essentially all cases and avoids complications from antiarrhythmic drugs 1.

Acute Management - Hemodynamically Stable Patients

Follow this algorithmic approach:

Step 1: Vagal Maneuvers (First-Line)

• Perform Valsalva maneuver with patient supine: bear down against closed glottis for 10-30 seconds (equivalent to 30-40 mmHg intrathoracic pressure) 1
• If unsuccessful, perform carotid sinus massage after confirming absence of bruit: apply steady pressure over right or left carotid sinus for 5-10 seconds 1
• Alternative: apply ice-cold wet towel to face (diving reflex) 1
• Success rate approximately 28% when switching between techniques 1
• Critical pitfall: Never apply pressure to eyeballs—this is dangerous and abandoned 1

Step 2: Adenosine (if vagal maneuvers fail)

• Adenosine terminates SVT in 90-95% of patients 1
• Side effects are minor and brief (<1 minute) in ~30% of patients 1
• Essential precaution: Have electrical cardioversion immediately available because adenosine may precipitate atrial fibrillation with rapid ventricular conduction, potentially causing ventricular fibrillation 1
• Watch for premature complexes after conversion that may reinitiate tachycardia—may require antiarrhythmic drug to prevent recurrence 1

Step 3: Alternative Pharmacologic Options (if adenosine fails or contraindicated)

• Intravenous diltiazem or verapamil: 64-98% success rate 1
  • Use slow infusion up to 20 minutes to minimize hypotension 1
  • Absolute contraindications: VT, pre-excited AF (WPW), suspected systolic heart failure 1
  • Critical warning: These agents can cause hemodynamic collapse or ventricular fibrillation if given for VT or pre-excited AF 1
• Intravenous beta blockers: Reasonable alternative with excellent safety profile, though less effective than calcium channel blockers 1

Step 4: Synchronized Cardioversion (if pharmacologic therapy fails)

• Perform after adequate sedation/anesthesia in stable patients 1
• Success rate 80-98% when combined with pharmacologic options 1

Special Consideration: Pre-excited Atrial Fibrillation (WPW Syndrome)

This is a distinct emergency requiring different management:

Unstable patients: Immediate synchronized cardioversion 1

Stable patients: Use ibutilide or IV procainamide—these slow accessory pathway conduction and may terminate AF 1

Absolutely avoid: AV nodal blockers (adenosine, beta blockers, diltiazem, verapamil, digoxin) can enhance accessory pathway conduction, causing rapid ventricular rates leading to ventricular fibrillation 1

---

Ventricular Tachycardia (VT) Management

Acute Management - Hemodynamically Unstable Patients

Immediate electrical cardioversion or defibrillation is required—do not attempt pharmacologic therapy first 2. VT in unstable patients demands urgent termination to prevent metabolic and hemodynamic decompensation.

Acute Management - Hemodynamically Stable Patients

The approach depends on whether structural heart disease is present:

Step 1: Assess for Structural Heart Disease

• VT with structural heart disease (ischemic/non-ischemic cardiomyopathy) has different implications than idiopathic VT 2, 3
• Distinguish monomorphic VT (usually structural) from polymorphic VT/VF (may indicate reversible causes or genetic syndromes) 2

Step 2: Immediate Termination Options

• Electrical cardioversion: Most reliable method 2
• Anti-tachycardia pacing: If ICD already implanted 2
• Antiarrhythmic drugs: May stabilize rhythm but have not shown mortality benefit 3

Step 3: Evaluate and Treat Reversible Causes

• Electrolyte abnormalities (hypokalemia, hypomagnesemia)
• Myocardial ischemia
• Proarrhythmic effects of antiarrhythmic drugs
• Metabolic derangements 4

Step 4: Prevent Recurrence

• Acute prevention: Antiarrhythmic drug therapy to prevent immediate recurrence 2
• Chronic prevention: Catheter ablation for recurrent VT, especially in structural heart disease 2, 3
• ICD consideration: For secondary prevention in appropriate candidates 5, 3

Special Consideration: Torsades de Pointes

Differentiate this polymorphic VT from standard VT/VF because antiarrhythmic therapy may be contraindicated 4. Treatment focuses on correcting QT prolongation (magnesium, pacing, removing offending drugs).

---

Critical Pitfalls to Avoid

1. Never give AV nodal blockers (adenosine, calcium channel blockers, beta blockers) for wide-complex tachycardia of uncertain origin—assume VT until proven otherwise to avoid catastrophic outcomes 1

2. Do not delay cardioversion in unstable patients attempting multiple pharmacologic interventions 1

3. Always have defibrillation capability available when giving adenosine due to risk of precipitating rapidly conducted AF 1

4. Avoid calcium channel blockers and beta blockers in systolic heart failure patients with SVT 1

5. Recognize that recurrent ICD shocks for VT indicate high morbidity/mortality—these patients need aggressive rhythm control strategies including catheter ablation 3

6. In patients with structural heart disease and VT, optimize heart failure management—this is crucial for long-term prognosis 2